Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Leronlimab will be needed in the future.
Bats Harbouring Six New Types of Coronavirus, Scientists Discover
like i have said before, i hope the cydy leronlimab works, but the many pr's issued by company creates doubt in my opinion
the facts will speak soon enough for cydy
It's an offshoot of "what's the dillio" which means I don't know a damn thing.
S.Korea Reports Recovered Coronavirus Patients Testing Positive Again
WHO called the news media?
It wasn't a trial and it wasn't great.
In the study, Gilead said, 84% of patients were either discharged from the hospital and/or saw at least a two-point improvement from baseline on a predefined six-point scale 28 days after receiving their first dose of remdesivir on March 7 or earlier. The company also said 17 of 30 patients on mechanical ventilation had their tubes removed within 28 days.
Clinical improvement was less frequent among patients on invasive ventilation versus noninvasive ventilation as well as with patients 70 years old or older.
Besides the side effects already mentioned tocilizumab suppresses the immune system. Not what you want when fighting a virus. It also inhibits only IL-6 whereas leronlimab controls many cytokines.
Per an email received by someone else on the board that shall not be named, Amarex submitted the trial protocol and it is being reviewed.
Study primary end date November 2020
https://clinicaltrials.gov/ct2/show/NCT04336410
An interesting take on CYDY.
CYDY Short
how many shares did you sell this week?
Sociopaths have no conscience.
Do you ever tire of getting proven wrong?
the companies hope to produce millions of vaccines by the end of 2020
"The treatment was administered at a leading medical center in the New York City area under an emergency Investigational New Drug (IND) recently granted by the U.S. Food and Drug Administration (FDA)."
https://www.cytodyn.com/newsroom/press-releases/detail/397/u-s-food-and-drug-administration-fda-grants-emergency
That sure does prove out the MOA of leronlimab.
That's an exact quotation from the video.
Ask them. I am quite happy you are holding your short position over the weeked. It should be another lesson for you to learn.
Results don't seem to beat leronlimab's.
so far, seven patients in the ICU with Acute Respiratory Distress Syndrome (ARDS) have been treated. All of the patients are alive, meaning that the survival rate is 100%, and six out of seven have progressed through at least one week of follow-up. On top of this, four patients saw respiratory parameters improve, one remained stable and only one demonstrated deterioration. Three are also in the advanced stages of being taken off ventilators.
Wrong
"Once we had a doctor, Doctor Hareesh from Montefiore Medical Center say that I want this drug under emergency IND and he injected four patients"
The right person in GILD is impressed with the results and talking about going to Dr Fauci.
Maybe GILD will enter into collaboration like PFE entered today with German company
Which means absolutely nothing.
Parts of contracts may be redacted in SEC filings if the information would put the company at a competitive disadvantage. The SEC wants an unredacted version to see if those parts excised would do so.
At this point Nader won't uplist until revenue. It's not far away and then you'll get caught flat-footed with your already upside down short position. How I will enjoy that day.
Will it?
Nothing but questions from a short bagholder. Someone smart would already have the answers.
If anyone were interested in starting a position in RBNW or wanting to add onto an existing position. IMHO now is an excellent time to be doing that.
Is the CEO hyping uplist?
Shame on him.
Leronlimab blocks a valid target for virus entry into the cells. Can a virus hit a different target to bypass this - that is the question?? Welcome educated responses.
Leronlimab at a minimum will be approved for Graft vs Host disease.
Might get approval for cancer but I doubt a game changer.
Which day? It certainly looks like an upward trend to me.
I thought you had read that SEC filing. Redemption starts at 6 months. It will be paid off before then.
CYDY stock up 672% in the last six months.
On December 10, 2018, Anthony D. Caracciolo resigned as the Chairman of the Board, but remains a director and Scott A. Kelly, M.D., was named Chairman of the Board. On December 19, 2018
I thought he used it to add mugs to his coffee cup collection.
One person can be two different things!!!! Doesn't that violate the laws of physics?
Where is the correct SEC report? Given a few years I'm sure you'll eventually find it.